Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Russell 2000 ETF (IWM) vs 10X Genomics Inc (TXG) Price & Performance

iShares Russell 2000 ETFTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

iShares Russell 2000 ETF vs 10X Genomics Inc — how do they compare? iShares Russell 2000 ETF trades at $278.54 (market cap $77.70B), while 10X Genomics Inc trades at $79 (market cap $10.07B). The key difference: iShares Russell 2000 ETF is far larger — about 7.7× 10X Genomics Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, iShares Russell 2000 ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Russell 2000 ETF for 83 Days and 10X Genomics Inc for 92 Days on average.

IWMTXG
Market Cap
$77.70B$10.07B
Volume
35,598,9835,657,286
52-Week High
$305.06$97.74
52-Week Low
$229.13$11.48
Typical Hold Time
83 Days92 Days
Sector
—Health
Enterprise Value
—$9.59B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Russell 2000 ETF

IWM trades at $277.72, down 1.27% amid broader small-cap weakness. Technical indicators show a bearish trend with resistance at $278 and support at $275. The ETF faces headwinds from Federal Reserve rate hikes and underperformance relative to large-cap indices over the past decade. Recent news highlights concerns about small-cap risk premiums and competition from more selective small-cap funds.

The outlook remains cautious as rising interest rates pressure small-cap valuations. Opportunities exist for long-term investors seeking diversification from tech-heavy large caps, but near-term risks include economic sensitivity and narrow market breadth. The bearish technical setup suggests further downside potential unless macroeconomic conditions improve.

10X Genomics Inc

10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.

TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IWM
78% Buy22% Sell
Avg holding period · 83 Days
TXG
4% Buy96% Sell
Avg holding period · 92 Days

Top news

Latest headlines on both assets

About iShares Russell 2000 ETF

The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.

Read more on IWM →

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG →